Gilead will donate Truvada for HIV prevention, but reaction is mixed
Seeking to blunt criticism of its pricing, Gilead is donating enough of its HIV prevention pill to cover as many as 200,000 patients over the next 11 years.
Seeking to blunt criticism of its pricing, Gilead Sciences (GILD) is donating enough of its HIV prevention pill to cover as many as 200,000 patients over the next 11 years. The donation will cover both the existing Truvada pill, which has been the subject of battles with AIDS activists, and still another drug the company hopes will also win regulatory approval to prevent the virus.
The move was hailed by the Trump administration, which announced plans to end HIV in the U.S. by 2030, but has also been criticized by activists for not taking
